ACARIZAX Meets Primary Objective in Phase 3 Bridging Trial in Chinese Participants with House Dust Mite Allergic Rhinitis – ALK
ALK announced positive topline results from the phase 3 bridging trial evaluating the efficacy and safety of its house dust mite (‘HDM’) sublingual immunotherapy (‘SLIT’) tablet, Acarizax, in… read more.
